The estimated Net Worth of David A Santos is at least 5.59 百万$ dollars as of 2 February 2024. Mr Santos owns over 14,519 units of Rigel Pharmaceuticals stock worth over 4,527,736$ and over the last 4 years he sold RIGL stock worth over 25,496$. In addition, he makes 1,034,977$ as Exec. VP & Chief Commercial Officer at Rigel Pharmaceuticals.
Mr has made over 2 trades of the Rigel Pharmaceuticals stock since 2023, according to the Form 4 filled with the SEC. Most recently he sold 14,519 units of RIGL stock worth 16,552$ on 2 February 2024.
The largest trade he's ever made was selling 14,519 units of Rigel Pharmaceuticals stock on 2 February 2024 worth over 16,552$. On average, Mr trades about 2,212 units every 41 days since 2020. As of 2 February 2024 he still owns at least 349,093 units of Rigel Pharmaceuticals stock.
You can see the complete history of Mr Santos stock trades at the bottom of the page.
David A. Santos is the Exec. VP & Chief Commercial Officer at Rigel Pharmaceuticals.
As the Exec. VP & Chief Commercial Officer of Rigel Pharmaceuticals, the total compensation of Mr Santos at Rigel Pharmaceuticals is 1,034,977$. There are no executives at Rigel Pharmaceuticals getting paid more.
Mr Santos is 58, he's been the Exec. VP & Chief Commercial Officer of Rigel Pharmaceuticals since . There are 2 older and 3 younger executives at Rigel Pharmaceuticals. The oldest executive at Rigel Pharmaceuticals is Raul R. Rodriguez, 60, who is the Pres, CEO & Director.
David's mailing address filed with the SEC is RIGEL PHARMACEUTICALS, INC., 611 GATEWAY BLVD, SUITE 900, SOUTH SAN FRANCISCO, CA, 94080.
Over the last 21 years, insiders at Rigel Pharmaceuticals have traded over 170,041,384$ worth of Rigel Pharmaceuticals stock and bought 2,068,700 units worth 7,281,949$ . The most active insiders traders include Partners L P/Ilbiotechnolog...、Ansbert Gadicke、Partners L P/Ilbiotechnolog.... On average, Rigel Pharmaceuticals executives and independent directors trade stock every 46 days with the average trade being worth of 961,207$. The most recent stock trade was executed by David A Santos on 2 February 2024, trading 14,519 units of RIGL stock currently worth 16,552$.
rigel pharmaceuticals, inc., is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases.
Rigel Pharmaceuticals executives and other stock owners filed with the SEC include: